Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| insulin-like growth factors | 5197 | 478166-15-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Mecasermin rinfabate [rDNA origin] injection is an aqueous solution for injection containing a binary protein complex of human insulin-like growth factor-1 (rhIGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3), both produced by recombinant DNA technology. The primary pharmacologic effect of IGF-1 in children is the promotion of linear growth. Secondary pharmacologic actions of IGF-1 include other anabolic effects, insulin sensitization, and insulin-like effects. There are no known direct growth-promoting effects of IGFBP-3. The primary effect of IGFBP-3 in the mecasermin rinfabate complex is the modulation of IGF-1 action.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 12, 2005 | FDA | INSMED |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AC05 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Laron-type isolated somatotropin defect | indication | 38196001 | DOID:9521 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| NZ8M50KKRG | UNII |
| 4025086 | VANDF |
| C1696547 | UMLSCUI |
| CHEBI:749578 | CHEBI |
| CHEMBL1201717 | ChEMBL_ID |
| DB14751 | DRUGBANK_ID |
| D04870 | KEGG_DRUG |
| 8437 | INN_ID |
| 422284004 | SNOMEDCT_US |
| 20793 | MMSL |
| d05692 | MMSL |
| 011373 | NDDF |
| 616877 | RXNORM |
None